NU SKIN ENTERPRISES, INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that NU SKIN ENTERPRISES, INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2013 | Dec 31, 2013 | $3.18B | Mar 18, 2014 |
| FY2012 | Dec 31, 2012 | $2.17B | Feb 27, 2013 |
| FY2011 | Dec 31, 2011 | $1.74B | Feb 28, 2012 |
| FY2011 | Dec 31, 2010 | $1.54B | Feb 28, 2012 |
| FY2011 | Dec 31, 2009 | $1.33B | Feb 28, 2012 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.49B | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $1.73B | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $1.97B | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $2.23B | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | $2.70B | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | $2.58B | Feb 16, 2023 |
| FY2021 | Dec 31, 2019 | $2.42B | Feb 16, 2022 |
| FY2020 | Dec 31, 2018 | $2.68B | Feb 11, 2021 |
| FY2019 | Dec 31, 2017 | $2.28B | Feb 13, 2020 |
| FY2018 | Dec 31, 2016 | $2.21B | Feb 14, 2019 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $2.28B | Feb 16, 2018 |
| FY2017 | Dec 31, 2016 | $2.21B | Feb 16, 2018 |
| FY2017 | Dec 31, 2015 | $2.25B | Feb 16, 2018 |
| FY2016 | Dec 31, 2014 | $2.57B | Feb 27, 2017 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.03B | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $1.18B | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $1.36B | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $1.59B | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | $2.02B | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | $1.92B | Feb 16, 2023 |
| FY2021 | Dec 31, 2019 | $1.84B | Feb 16, 2022 |
| FY2020 | Dec 31, 2018 | $2.04B | Feb 11, 2021 |
| FY2019 | Dec 31, 2017 | $1.78B | Feb 13, 2020 |
| FY2018 | Dec 31, 2016 | $1.71B | Feb 14, 2019 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $160.20M | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | ($146.59M) | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $8.60M | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $104.78M | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | $147.27M | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | $191.36M | Feb 16, 2023 |
| FY2021 | Dec 31, 2019 | $173.55M | Feb 16, 2022 |
| FY2020 | Dec 31, 2018 | $121.89M | Feb 11, 2021 |
| FY2019 | Dec 31, 2017 | $129.44M | Feb 13, 2020 |
| FY2018 | Dec 31, 2016 | $143.09M | Feb 14, 2019 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $65.76M | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | ($151.59M) | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $48.27M | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $110.85M | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | $233.99M | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | $257.56M | Feb 16, 2023 |
| FY2021 | Dec 31, 2019 | $267.43M | Feb 16, 2022 |
| FY2020 | Dec 31, 2018 | $240.86M | Feb 11, 2021 |
| FY2019 | Dec 31, 2017 | $274.48M | Feb 13, 2020 |
| FY2018 | Dec 31, 2016 | $231.10M | Feb 14, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $10.80M | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $13.00M | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $22.60M | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $23.30M | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | $27.20M | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | $23.30M | Feb 16, 2023 |
| FY2021 | Dec 31, 2019 | $30.10M | Feb 16, 2022 |
| FY2020 | Dec 31, 2018 | $23.00M | Feb 11, 2021 |
| FY2019 | Dec 31, 2017 | $22.00M | Feb 13, 2020 |
| FY2018 | Dec 31, 2016 | $24.30M | Feb 14, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $80.29M | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $111.74M | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $118.64M | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $108.06M | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | $141.58M | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | $379.14M | Feb 16, 2023 |
| FY2021 | Dec 31, 2019 | $177.93M | Feb 16, 2022 |
| FY2020 | Dec 31, 2018 | $202.74M | Feb 11, 2021 |
| FY2019 | Dec 31, 2017 | $302.56M | Feb 13, 2020 |
| FY2018 | Dec 31, 2016 | $275.26M | Feb 14, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $34.28M | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $41.58M | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $58.49M | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $59.06M | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | $68.62M | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | $63.82M | Feb 16, 2023 |
| FY2021 | Dec 31, 2019 | $66.07M | Feb 16, 2022 |
| FY2020 | Dec 31, 2018 | $70.37M | Feb 11, 2021 |
| FY2019 | Dec 31, 2017 | $60.16M | Feb 13, 2020 |
| FY2018 | Dec 31, 2016 | $50.22M | Feb 14, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.41B | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $1.47B | Feb 13, 2026 |
| FY2024 | Dec 31, 2023 | $1.81B | Feb 14, 2025 |
| FY2023 | Dec 31, 2022 | $1.82B | Feb 15, 2024 |
| FY2022 | Dec 31, 2021 | $1.91B | Feb 16, 2023 |
| FY2021 | Dec 31, 2020 | $1.96B | Feb 16, 2022 |
| FY2020 | Dec 31, 2019 | $1.77B | Feb 11, 2021 |
| FY2019 | Dec 31, 2018 | $1.69B | Feb 13, 2020 |
| FY2018 | Dec 31, 2017 | $1.59B | Feb 14, 2019 |
| FY2017 | Dec 31, 2016 | $1.47B | Feb 16, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $600.07M | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $817.46M | Feb 13, 2026 |
| FY2024 | Dec 31, 2023 | $986.66M | Feb 14, 2025 |
| FY2023 | Dec 31, 2022 | $923.67M | Feb 15, 2024 |
| FY2022 | Dec 31, 2021 | $993.71M | Feb 16, 2023 |
| FY2021 | Dec 31, 2020 | $1.06B | Feb 16, 2022 |
| FY2020 | Dec 31, 2019 | $893.72M | Feb 11, 2021 |
| FY2019 | Dec 31, 2018 | $912.58M | Feb 13, 2020 |
| FY2018 | Dec 31, 2017 | $885.28M | Feb 14, 2019 |
| FY2017 | Dec 31, 2016 | $809.98M | Feb 16, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $805.24M | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $651.46M | Feb 13, 2026 |
| FY2024 | Dec 31, 2023 | $821.97M | Feb 14, 2025 |
| FY2023 | Dec 31, 2022 | $897.30M | Feb 15, 2024 |
| FY2022 | Dec 31, 2021 | $912.77M | Feb 16, 2023 |
| FY2021 | Dec 31, 2020 | $894.27M | Feb 16, 2022 |
| FY2020 | Dec 31, 2019 | $875.29M | Feb 11, 2021 |
| FY2019 | Dec 31, 2018 | $781.87M | Feb 13, 2020 |
| FY2018 | Dec 31, 2017 | $704.60M | Feb 14, 2019 |
| FY2017 | Dec 31, 2016 | $664.07M | Feb 16, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $83.63M | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $83.63M | Feb 13, 2026 |
| FY2024 | Dec 31, 2023 | $218.17M | Feb 14, 2025 |
| FY2023 | Dec 31, 2022 | $206.43M | Feb 15, 2024 |
| FY2022 | Dec 31, 2021 | $206.43M | Feb 16, 2023 |
| FY2021 | Dec 31, 2020 | $202.98M | Feb 16, 2022 |
| FY2020 | Dec 31, 2019 | $196.57M | Feb 11, 2021 |
| FY2019 | Dec 31, 2018 | $196.57M | Feb 13, 2020 |
| FY2018 | Dec 31, 2017 | $114.95M | Feb 14, 2019 |
| FY2017 | Dec 31, 2016 | $114.95M | Feb 16, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.86B | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $1.71B | Feb 13, 2026 |
| FY2024 | Dec 31, 2023 | $1.87B | Feb 14, 2025 |
| FY2023 | Dec 31, 2022 | $1.94B | Feb 15, 2024 |
| FY2022 | Dec 31, 2021 | $1.91B | Feb 16, 2023 |
| FY2021 | Dec 31, 2020 | $1.84B | Feb 16, 2022 |
| FY2020 | Dec 31, 2019 | $1.73B | Feb 11, 2021 |
| FY2019 | Dec 31, 2018 | $1.64B | Feb 13, 2020 |
| FY2018 | Dec 31, 2017 | $1.61B | Feb 14, 2019 |
| FY2017 | Dec 31, 2016 | $1.56B | Feb 16, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $238.63M | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $186.88M | Feb 13, 2026 |
| FY2024 | Dec 31, 2023 | $256.06M | Feb 14, 2025 |
| FY2023 | Dec 31, 2022 | $264.73M | Feb 15, 2024 |
| FY2022 | Dec 31, 2021 | $339.59M | Feb 16, 2023 |
| FY2021 | Dec 31, 2020 | $402.68M | Feb 16, 2022 |
| FY2020 | Dec 31, 2019 | $335.63M | Feb 11, 2021 |
| FY2019 | Dec 31, 2018 | $386.91M | Feb 13, 2020 |
| FY2018 | Dec 31, 2017 | $426.40M | Feb 14, 2019 |
| FY2018 | Dec 31, 2016 | $357.25M | Feb 14, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2015 | Dec 31, 2015 | $253.90M | Feb 18, 2016 |
| FY2014 | Dec 31, 2014 | $252.79M | Mar 2, 2015 |
| FY2013 | Dec 31, 2013 | $181.68M | Mar 18, 2014 |
| FY2012 | Dec 31, 2012 | $193.98M | Feb 27, 2013 |
| FY2011 | Dec 31, 2011 | $136.55M | Feb 28, 2012 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 3 | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | (2) | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | 2 | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | 2 | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | 3 | Feb 16, 2023 |
| FY2021 | Dec 31, 2019 | 3 | Feb 16, 2022 |
| FY2020 | Dec 31, 2018 | 2 | Feb 11, 2021 |
| FY2019 | Dec 31, 2017 | 2 | Feb 13, 2020 |
| FY2018 | Dec 31, 2016 | 2 | Feb 14, 2019 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 3 | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | (2) | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | 2 | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | 2 | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | 3 | Feb 16, 2023 |
| FY2021 | Dec 31, 2019 | 3 | Feb 16, 2022 |
| FY2020 | Dec 31, 2018 | 2 | Feb 11, 2021 |
| FY2019 | Dec 31, 2017 | 2 | Feb 13, 2020 |
| FY2018 | Dec 31, 2016 | 2 | Feb 14, 2019 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $11.83M | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $11.93M | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $77.62M | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $77.02M | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | $76.27M | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | $78.39M | Feb 16, 2023 |
| FY2021 | Dec 31, 2019 | $82.19M | Feb 16, 2022 |
| FY2020 | Dec 31, 2018 | $80.58M | Feb 11, 2021 |
| FY2019 | Dec 31, 2017 | $76.06M | Feb 13, 2020 |
| FY2018 | Dec 31, 2016 | $78.44M | Feb 14, 2019 |